Ratings by Citi (Peter Verdult)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 9/13/2024 | Eli Lilly | LLY | New Coverage | Buy (N/A) |
920.89 (1149.36) |
24.81% | Details | |
| 1/12/2023 | Sanofi-Aventis | SNY | New Coverage | Buy (N/A) |
48.82 (44.24) |
-9.38% | Details | |
| 12/20/2022 | Genmab A/S | GMAB | Downgrade | Neutral (Buy) |
43.04 (33.60) |
-21.93% | Details | |
| 1/27/2022 | Galapagos NV | GLPG | Upgrade | Buy (Neutral) |
53.15 (27.73) |
-47.83% | Details | |
| 1/7/2022 | Evotec | EVO | New Coverage | Neutral (N/A) |
22.07 (1.86) |
-91.57% | Details | |
| 9/20/2018 | Bayer AG | BAYRY | Upgrade | Buy (Neutral) |
21.46 (14.19) |
-33.88% | Details | |
| 8/21/2018 | Sanofi-Aventis | SNY | Maintain | Buy (N/A) |
|
Details | ||
| 8/21/2018 | Merck KGaA (ADR) | MKKGY | Maintain | Buy (N/A) |
|
Details | ||
| 8/13/2018 | Bayer AG | BAYRY | Downgrade | Neutral (Buy) |
27.60 (21.46) |
-22.25% | Details |
